LONDON (Reuters) - Rapid advances in cancer science have increased the number of new oncology drugs being developed, but delays in regulation and approvals mean patients in Europe often wait years to be able to access them, researchers said on Tuesday.
A report led by Britain's Institute for Cancer Research (ICR) found the average time from the start of a drug's early stage, or Phase I, clinical trials to a marketing licence being granted by European Medicines Agency (EMA) regulators grew to 9.1 years in 2009 to 2016, from 7.8 years in 2000 to 2008.